This Viewpoint discusses whether the changes in the health care marketplace, the evolution of precision medicine, and the uniqueness of drug development and labeling for cancer diagnoses make the Orphan Drug Act less necessary and less relevant today than at its inception.
No takes yet. Share an insight, caveat, or question.
Nabhan et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: